Background {#Sec1}
==========

Inborn errors of metabolism (IEMs) are defined as monogenic diseases that result in dysfunctional proteins encoded by different genes, which in many cases lead to loss of activity of the enzymes involved \[[@CR1]\]. More than 600 different inborn errors of metabolism have been recognized up to this point, and this number is constantly increasing as new concepts and techniques become available for identifying biochemical phenotypes. IEMs are extremely heterogeneous making their classification a primary challenge. Several informal systems of classification currently exist. IEMs can be classified according to the organs involved, such as neurological or hepatic disorders or according to the organelle involved, such as mitochondrial, peroxisomal or lysosomal disorders. Disorders can also be classified according to the age of presentation ranging from neonatal onset to juvenile and adult onset. Because each of these approaches may depend upon the actual setting, no single classification is universally applied \[[@CR2]\]. One common and informative classification system involves the classification of IEMs into small and large molecule disorders \[[@CR3]\]. Small molecule IEMs have an acute intoxication presentation with a remitting-relapsing clinical course. These include organic acidemias, vitamin responsive disorders, urea cycle disorders, inborn errors of carbohydrates, haem synthesis defects, cholesterol biosynthesis defects, and amino acids and metal transport defects. Large molecule IEMs have a gradual and insidious progressive presentation. These include glycogen storage disorders, sphingolipidosis, mucopolysaccharidosis, oligosaccharidosis, mitochondrial disorders and congenital disorders of glycosylation \[[@CR2]\]. The diagnosis of IEMs is mainly based on biochemical investigations, which include the screening of several metabolites in the blood, urine and cerebrospinal fluid (CSF); analysis of enzymatic activities, and molecular genetics testing.

The incidence of such disorders vary from country to country and from region to region. In one Australian study the incidence was reported to be 15.7 per 100,000 births whereas, in Italy, the reported incidence was 27 per 100,000 births \[[@CR4], [@CR5]\]. In the West Midlands region in the United Kingdom (UK), the incidence reached up to 1:784 and in British Columbia, Canada, the incidence was reported to be 1:2500 \[[@CR6], [@CR7]\].

These disorders are usually inherited as autosomal recessive disorders, explaining why IEMs are common in populations with a high rate of consanguineous marriages, such as Saudi Arabia. In Saudi Arabia, the rate of consanguineous marriages reaches up to approximately 60 % \[[@CR8], [@CR9]\].

Despite the high frequency of IEMs, apart from the eastern region study \[[@CR10]\], only a few anecdotal epidemiological studies in Saudi Arabia have discussed the incidence, type and distribution of such devastating disorders. Most of the remaining reports in the literature were limited to case reports and case series. In this study, we report the incidence, type, and distribution of IEMs presenting to King Abdulaziz Medical City (KAMC) in the middle region of Saudi Arabia over 13 years. In addition, we identified 43 novel mutations.

Methods {#Sec2}
=======

King Abdulaziz Medical City (KAMC) is a tertiary center in Saudi Arabia, that commenced operations in 1983. The bed capacity is 715, and an average of 8500 births per year occur at the center. This medical city passed the requirements for accreditation under the Joint Commission International (JCI) standards with excellent performance in December 2006. The current study is a retrospective review of all cases at the Pediatric Department of King Abdulaziz Medical City (KAMC) in Riyadh, Saudi Arabia. The duration of the study was 13 years, from 01-01-2001 to 31-12-2014. All patients included were born during this period. The cases were identified according to medical records via diagnostic codes and the genetic division's database. The study was approved by the research committee of King Abdullah International Medical Research Centre (KAIMRC) in Riyadh, Saudi Arabia.

The diagnostic algorithm starts by referring patients based on clinical suspicion to genetic/metabolic facility from other departments, and from positive new born screening (NBS) after 2011. All accepted cases undergo phenotype related screening biochemical investigations. Confirmation of diagnosis is then achieved either by measuring enzyme activity and/or by targeted molecular tests. In case of unrevealing confirmatory investigations or vague presentation, whole exome or whole genome sequencing is requested.

The diagnosis of each IEM was based on clinical and biochemical investigations, including analyses of ammonia, lactic acid, total homocysteine, plasma amino acids, the acylcarnitine profile, urine aminoacids, urine for organic acids, copper, ceruloplasmine levels, very long chain fatty acids, transferrin isoelectrofocusing, carbohydrate-deficient transferrin and urine for polyols.

DNA molecular genetic testing was performed in commercial clinical international labs including CENTOGENE, GeneDx, Emory Genetics, Cincinnati Children's Hospital Medical Center, Bioscientia and Nijmegen Medical Center. All of the parents of the patients with IEMs were tested for carrier status.

Incidence was calculated by dividing the number of diagnosed cases by the number of total births during the study period and multiplying by 100,000 \[[@CR11]\].

Results {#Sec3}
=======

Over the 13-year period of this retrospective cohort study, the total number of live births reached 110,601. A total of 187 patients were diagnosed with an IEM, resulting in an incidence of 169 in 100,000 births (1:591). Of these patients, 121 (64.7 %) were identified to have a small molecule disease (Table [1](#Tab1){ref-type="table"}) and 66 (35.3 %) to have a large molecule disease (Table [2](#Tab2){ref-type="table"}). The overall mean, median and range of age at diagnosis were 3.2 years, 1.2 years and from 1 day to 13 years respectively. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} show the type and distribution of IEMs from 2001 to 2014 and illustrate the estimated incidence per 100,000 live births for each group of disorders and the mean, median and range of age at diagnosis for each group. The lysosomal storage disorders (LSDs) were the most common diagnosed group, in general, and were observed in 39/187 patients (20.8 %). Sphingolipidoses represent the largest subgroup of the LSDs (22/39; 56.4 %), and GM1 gangliosidosis (infantile phenotype) was the most prevalent disorder. The second most common category was organic acidemias (34/187; 18.2 %), with propionic acidemia (PA) as the most common disorder in that group. Aminoacidopathies were diagnosed in 30/187 patients (16 %). Fatty acid oxidation defects (FAOD) were diagnosed in 5/187 patients (2.7 %), and the frequency of patients with urea cycle disorders (UCD) was 12/187 (6.4 %). The most common FAOD was very long-chain acyl-CoA dehydrogenase deficiency (VLCAD), while argininosuccinic aciduria was the most common UCD. Mucopolysaccharidoses (MPS) were diagnosed in 15/187 patients (8 %), with MPS VI as the predominant type. Fourty-three novel mutations were identified, and missense mutations were the most common type of mutations (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). All the listed novel mutations fit with the clinical features of the disease, biochemical biomarkers support genotype phenotype correlation and they segregate well within the patients and family members.Table 1Small-molecule disorders of IEMs in KAMC (2001--2014). Total numbers of live births (110,601)Disease categoryNumber of cases diagnosedIncidence per 100,000Mean age at diagnosisMedian age at diagnosisRange of ageOrganic acidemias34301.8 years60 days1 day--10 yearsPropionic acidemia930.2 days20 days1 day--6 monthsMethylmalonic acidemia7Mutase deficiency5Cobalamin A defect1Cobalamin C defect1Glutaric acidemia33-hydroxy-3-methylglutaryl-CoA lyase deficiency43-Methylcrotonylco A carboxylase deficiency3Biotinidase deficiency33-Methylglutaconic Aciduria Type III1Ethylmalonic encephalopathy1B-ketothiolase deficiency1Isovaleric acidemia1Malonic aciduria1Aminoacidopathies30273.3 years10.5 months1 day--13 yearsHomocystinuria147 years7.5 years • Classical11 • MTHFR deficiency2 • MAT deficiency1PKU5 • Classical3 • Non-PKU hyperphenylalaninemia2Biopterin Synthesis Defect PTPS deficiency4MSUD5Asparagine synthetase deficiency2Vitamins responsive disorders18165.7 years5.5 years6 months--10 yearsBiotin Thiamine Responsive Basal Ganglia Disease17Pyridoxine-dependent epilepsy1Inborn Errors of Carbohydrates12113.1 years1.3 years1 week--7 yearsGalactosemia4Transaldolase deficiency6Hereditary fructose intolerance1Fructose 1,6 bisphosphatase deficiency1Urea Cycle Disorders121112 days7 days1 day--30 daysArgininosuccinic Aciduria8Citrullinemia4Fatty Acid Oxidation Defects541.4 years2 days2 days--7 yearsVLCAD deficiency321 days2 days2 days--60 daysMCAD deficiency12 days2 days2 daysCarnitine uptake defect17 years7 years7 yearsAminoacids transport defect5410 years11 years6--13 yearsCystinuria5Metal transport defect228.5 years8.5 years7--10 yearsWilson disease2Disorders of Haem biosynthesis2212.5 years12.5 years12--13 yearsAcute intermittent porphyria2Cholesterol biosynthesis defect111 year1 year1 yearCHILD syndrome1Total1211093.3 years9 months1 day--13 years*MTHFR* methylenetetrahydrofolatereductase, *MAT* methionine adenosyltransferase, *PKU* phenylketonuria, *MSUD* maple syrup urine disease, *VLCAD* very long-chain acyl-CoA dehydrogenase, *MCAD* medium-chain acyl-CoA dehydrogenase, *CHILD* Congenital hemidysplasia with ichthyosiform erythroderma and limb defects, *PTPS* 6-Pyruvoyl-Tetrahydropterin SynthaseTable 2Large-molecule disorders of IEMs in KAMC (2001--2014). Total numbers of live births (110,601)Disease categoryNumber of cases diagnosedIncidence per 100,000Mean age at diagnosisMedian age at diagnosisRange of ageLysosomal Storage Diseases (LSD)41373.6 year3 years2 months--13 yearsSphingolipidosis22203.1 years2 years2 months--13 yearsFabry disease3Sandhoff disease2Niemann--Pick disease type B1Niemann--Pick disease type C3GM1 gangliosidosis (infantile phenotype)4Metachromatic leukodystrophy3Saposin B Deficiency2Krabbe disease1Mucopolysaccharidosis (MPS)15145 years5 years5 months--12 yearsMPS I1MPS II1MPS IIIA2MPS IVA5MPS VI6Oligosaccharidosis223 years3 years2--4 yearsMucolipidosis II1α-mannosidosis1OthersNeuronal ceroid-lipofuscinoses3: 2 type 6, and 1 type 85.355--6 yearsGSD II23.1 months3.1 months1 week to 6 monthsGlycogen storage diseases (GSD)542.2 years2 years15 months--4 yearsGSD III1GSD IV1GSD IX3Mitochondrial disorders12112.2 years8 months1 week--8 yearsLeigh disease3Pyruvate dehydrogenase deficiency2Pyruvate carboxylase deficiency2Mitochondrial DNA depletion syndrome 31Mitochondrial DNA depletion syndrome 51Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 113-Methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like1Primary Coenzyme Q10 deficiency type 51Peroxisomal disorders762 years9 months1 week--8 yearsPrimary hyperoxaluria type 15Zellweger syndrome1Rhizomelic Chondrodysplasia Punctata1Congenital disorders of glycosylation (CDG)1 (CDG 1 L)18 years8 years8 yearsTotal66603.1 years2 years1 week--13 yearsTable 3Mutations for small molecule IEMsDisease categoryDiseaseGeneReported mutationsNovel mutationsFounder Vs. PrivateType of mutationOrganic acidemiasPropionic acidemia*PCCA*c.425G \> A(p. Gly142Asp)FounderHomozygous, missensec.350G \> A (p.Gly117Asp)Private*PCCB*c.1050dupTPrivateDupplicationMethylmalonic acidemia*MUT*c.329 A \> G(p. Tyr110Cys)FounderHomozygous, missense,c.1677-1G \> CPrivateSpliceCobalamin A Defect*MMAA*c.586C \> T (p.Arg196\*)PrivateNonsenseCobalamin C defect*MMACHC*c.394C \> T (p. Arg132\*)PrivateNonsenseGlutaric acidemia*GCDH*c.1144G \> A (p.Ala382Thr)Privatemissensec.853-2A \> G (IVS8-2A \> G)PrivateSplicec.278A \> G (p.His93Arg)Privatemissense3-hydroxy-3-methylglutaryl-CoA lyase deficiency*HMGCL*c.122G \> AFoundermissense3-Methylcrotonyl CoA carboxylase deficiency*MCCC1*c.1808 dup A(p. p.Asn603 Lysfs\*5)PrivateHomozygous, duplication*MCCC2*c.1147A \> T (p.Lys383\*)PrivateNonsenseBiotinidase deficiency*BTD*c.755A \> G (p.Asp252Gly)\
c.1330G \> C (p.Asp444His)PrivateTwo heterozygous missense mutations in Exon 43-Methylglutaconic aciduria type III*OPA3*c.194delG(p. Gly65Alafs\*7)PrivateHomozygous, deletionEthylmalonic encephalopathy*ETHE1*c.263 C \> T(p. Ser88Leu)PrivateHomozygous, missenseB-Ketothiolase deficiency*ACAT1*c.412-419del(p. Gln138Tyrfs\*36)PrivateHomozygous, deletionIsovaleric acidemia*IVD*c.358C \> T(p. Arg120X)PrivateHomozygous, nonsenseMalonyl-CoA decarboxylase deficiency*MLYCD*c.953_954delAG(p. Glu318Valfs\*35)PrivateHomozygous, deletionAminoacidopathiesHomocystinuriaClassical*CBS*c.969G \> A (p.Trp323Ter)FounderHomozygous missensec.1006C \> T (p.Arg336Cys)FounderHomozygous missenseMTHFR deficiency*MTHFR*c.680C \> T (p.Thr227Met)PrivateMAT deficiency*MAT1A*c.1081G \> T(p.Val361Phe)PrivateHomozygous, missensePKU*PAH*c.1169A \> G (p.Glu390Gly)PrivateHomozygous, missensePTPS deficiency*PTPS*c.238A \> G(p. Met80Val)FounderHomozygous, missensec.169_171delGTG (p.Val57del)FounderHomozygous, deletionMSUD*BCKDHA*c.347A \> G(p. Asp116Gly)Privatemissensec.905A \> C (p.Asp302Ala)Foundermissense*BCKDHB*c.674 T \> C(p.Leu225Pro)Privatemissensec.1144 T \> C(p.Cys382Arg)PrivateHomozygous, missenseAsparagine synthetase deficiency*ASNS*c.1160A \> G (p.Tyr377Cys)FounderHomozygous, missenseVitamins responsive disordersBiotin Thiamine Responsive Basal Ganglia Disease*SLC19A3*c.1264A \> G (p.Thr422Ala)FounderHomozygous, missensePyridoxine-dependent epilepsy*ALDH7A1*c.877dupAA (p.Ser293Lysfs\*22)PrivateDuplicationInborn Errors of CarbohydratesGalactosemia*GALT*c.691 C \> T (p.Arg231Cys)FounderHomozygous, missensec.404C \> T (p.Ser135Leu)PrivateHomozygous, missensec.563A \> G (P.Gln188Arg)PrivateHomozygous, missenseTransaldolase Deficiency*TALDO1*c.793delC (p.Gln265ArgfsX56)FounderDeletionHereditary fructose intolerance*ALDOB*c.360_363delCAAA (p.Asn119LysfsX31)PrivateDeletionFructose 1,6 bisphosphatase deficiency*FBP1*c.114_119dup (p. Cys39_Thr40dup)PrivateDuplicationUrea cycle disordersArgininosuccinic Aciduria*ASL*c.556C \> T (p.Arg186Trp)FounderMissensec.1060C \> T (p.Q354X)FounderNonsenseCitrullinemia type 1*ASS1*c.364-2A \> GFounderHomozygous, intronicc.370G \> A (p.Asp124Asn)FounderHomozygous, missenseFatty acid oxidation defectVLCAD*ACADVL*c.494 T \> C(Phe165Ser)PrivateHomozygous, missenseVLCAD*ACADVL*c.65C \> A (p.Ser22\*)FounderNonsenseMCAD*ACADM*c.255 G \> T(p.Gly119\*);)PrivateHomozygous, nonsensec.938 T \> G(p.Phe313CysPrivateHomozygous, missenseCarnitine uptake defect*SLC22A5*c.1385G \> A(p. Gly462Asp)PrivateHomozygous, missenseAminoacids transport defectCystinuria*SLC3A1*c.1711 T \> A(p.Cys571Ser)FounderHomozygous, missensec.1400 T \> A (p.Met467Lys)Private*SLC7A9*c.1166 C \> T(p.Thr389Met)PrivateHomozygous, missenseMetal Transport DefectWilson disease*ATP7B*c.2230 T \> C (p.Ser744Pro)FounderHomozygous, missenseDisorders od Haem biosynthesisAcute Intermittent Poephyria*HMBS*c.760delC (p.Leu254X)FounderNonsenseCholesterol biosynthesis defectCHILD syndrome*NSDHL*c.314C \> T (p.Ala105Val)PrivateHomozygous, missense*PKU* phenylketonuria, *MSUD* maple syrup urine disease, *VLCAD* very long-chain acyl-CoA dehydrogenase, *MCAD* medium-chain acyl-CoA dehydrogenaseTable 4Mutations for large molecule IEMsDisease categoryDiseaseGeneReported mutationsNovel mutationsFounder Vs. PrivateType of mutationLSDSphingolipidosisFabry*GLA*c. 782G \> T (p.Gly261Val)FounderHomozygous, missenseSandhoff disease*HEXB*c.1169 + 3_1169 + 10delAAGTTGTT (p.Gly65 AlafsX7)PrivateDeletionNiemann-Pick disease type B*SMPD1*c.1267 C \> T (p.His423Tyr)FounderHomozygous, missenseNiemann-Pick disease type C*NPC1*c.2130 + 1G \> A;FounderHomozygous, intronicc.2443_2444delp.ser815Leufs\*54PrivatedeletionGM1 gangliosidosis*GLB1*c.950G \> A(p. Trp317\*)PrivateHomozygous, nonsensec.171C \> G (p.Tyr57X)FounderHomozygous, missenseMetachromatic leukodystrophy*ARSA*c.1108-2A \> GPrivateHomozygous, intronicSaposin B deficiency*PSAP*c.722G \> C (p.Cys241SerFounderHomozygous, missenseKrabbe disease*GALC*c.396G \> A(p.Trp132\*)PrivateHomozygous, nonsenseMucopolysaccharidosis (MPS)MPSI*IDUA*c.1868 T \> C(p. Leu623Pro)PrivateHomozygous, missenseMPSII*IDS*c.405A \> C(p. Lys135Asn)PrivateHomozygous, missenseMPSIIIA*SGSH*c.664-13C \> GPrivateHomozygous, intronicc.535G \> A (p.Asp179Asn)PrivateHomozygous, missenseMPS IVA*GALNS*c.120 + 1G \> C (IVS1 + 1G \> C)PrivateHomozygous, missensec.860C \> T (p.Ser287Leu)PrivateHomozygous, missensec.697G \> A (p.Asp233Asn)PrivateHomozygous, missenseMPSVI*ARSB*c.753C \> G (p.Tyr251\*)FounderHomozygous, nonsensec.430A \> G (p.His393ARG)FounderHomozygous, missensec.1079 T \> C (p. Leu360Pro)PrivateHomozygous, missenseOligosaccharidosisMucolipidosis II*GNPTAB*c.3503_3504 delTC (p.Phex1172)PrivateHomozygous, deletionα-mannosidosis*MAN2B1*c.1340A \> T (p.Asp447Val)PrivateHomozygous, missenseOthersNCL type 6*CLN6*c.794_796del(p.Ser265del)PrivateHomozygous, deletionc.794_796delCCTPrivateHomozygous, deletionNCL type 8*CLN8*Homozygous deletion encompassing exon2PrivateHomozygous, deletionGSDII*GAA*c.1431delT(p. lle477fs)PrivateHomozygous, deletionc.1657C \> T(p. Gln553\*)PrivateHomozygous nonsenseGlycogen storage diseaseGSDIII*AGL*c.4353G \> T(p. Trp1451Cys);PrivateHomozygous, missenseGSDIV*GBE1*c.998A \> T (p.Glu 333 Val)PrivateHomozygous, missenseGSD IX*PHKG2*c.130C \> T (p.Arg44\*)FounderHomozygous nonsense*PHKB*Deletion Exon 5 and 6PrivateHomozygous, deletionMitochondrial disordersLeigh disease*MTATP6*m.8993 T \> G (p.Leu156Arg)PrivateHomoplasmic, missense*COX15*c.649C \> T (p.Arg217Trp)PrivateHomozygous, missensePyruvate dehydrogenase deficiency*PDHA1*c.1256_1259dup (p.Trp421Serfs\*6)PrivateHeterozygous Duplication*PDHA1*c.1132C \> T (p.Arg378Cys)PrivateHemizygous missensePyruvate Carboxylase Deficiency*PC*c.3116_3126del (p.Leu1039Glnfs\*7)PrivateDeletionMitochondrial DNA depletion syndrome 3*DGUOK*c. 617G \> A (p. R206k)PrivateHomozygous, missenseMitochondrial DNA depletion syndrome 5*SUCLA2*c.362_363del (p.Ile121Serfs\*38)PrivateDeletionCardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1*SCO2*c.2 T \> C(p.Met1?)PrivateHomozygous, missense3-Methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like*SERAC1*c.438del (p.Thr147Argfs\*22)PrivateDeletionPrimary CoenzymeQ10 deficiency type 5*COQ9*chr16_57485062C \> T (p.His62Arg)PrivateHomozygous, missensePeroxisomal disordersPrimary hyperoxaluria type 1*AGXT*c.187G \> C (p.Gly63Arg)FounderHomozygous, missenseZellweger syndrome*PEX5*c.1578 T \> G (p.Asn526Lys)PrivateHomozygous, missenseRhizomelic chondrodysplasia punctata type 1*PEX7*c.321_322delTA(p.Tyr107\*)PrivateHomozygous, deletionCongenital disorder of glycosylation (CDG)CGD 1 L*ALG9*c.1075G \> A (p.E359K)PrivateHomozygous, missense

Discussion {#Sec4}
==========

In this report, we describe the incidence of IEMs in a single tertiary center in the middle region of Saudi Arabia over more than a decade. We reported an incidence of 1:591 individuals, which is the highest incidence for IEMs reported to this point. Our study is the second epidemiological report after that of Moammar et al., 2010, who reported a incidence of 1:667 \[[@CR10]\]. If we combine the two studies, the cumulative incidence is 1:635 births or 157 per 100,000, which is still one of highest reported incidence rates across the world. KAMC is one of the largest medical institutions in the Kingdom and is also a referral center; therefore to obtain a more accurate estimation of incidence of these disorders we have excluded the 69 patients who were diagnosed with IEM but not born at KAMC. If we combine the referred cases with those of patients born at the hospital, we obtain an incidence of 231.5 in 100,000 births (1:432).

Our study confirms the conclusions drawn by Moammar et al., 2010, LSDs are the most commonly identified group of disorders and organic acidemias are the most prevalent small molecule diseases. Our work also supports the notion that MPS VI is the most common type of mucopolysaccharidosis in Saudi Arabia. The results also support the wide variation in incidence of genetic diseases between Saudi Arabia and other parts of the world \[[@CR12]\]. In our study for example the recorded number of PTPS exceeds the classical PKU which is reverse in Caucasian population \[[@CR13]\]. This is more evident in PA, in which incidence in Saudi Arabia far exceeds the global incidence \[[@CR14]\]. During the course of our study we discovered 9 new PA cases in our center, with incidence of 1 per 12,500 live births.

Our study showed unique phenotypes in comparison with the literature. Our three VLCAD patients for example had early presentation with severe phenotype ended with early death. Their genotype mutations were one novel missense mutation in exon 6, c.494 T \> C (p.Phe165Ser) and the other two had previously reported nonsense mutation in exon 2, c.65C \> A (p.Ser22\*). Although these mutations are not clear null mutations \[[@CR15]\], they resulted in severe phenotype. Alternatively, the most common phenotype in VLCAD is the milder late onset with the missense mutation p.Val283Ala being the most prevalent disease causing variant \[[@CR15]\]. This reflect the poor genotype-phenotype correlation.

In this study the number of private mutations was almost double that of founder mutations, which support the previous report of Al-Owain et.al (2012) who noted that private mutations outweigh founder mutations in Saudi Arabia \[[@CR12]\].

Interestingly, among the diseases discovered by our study, 35 diseases are amenable for treatment. Recent advances in early diagnostic tools like the expanded New Born Screening program list, which can detect 14 of the listed diseases, and the availability of treatment options like enzyme replacement therapy, opened new horizons for these patients and their families.

With the implementation of next generation sequencing (WES and WGS) we were able to solve many obscure cases. Additionally, new diseases and new variants might be discovered more easily. It is possible to see NGS a first line diagnostic tool in the near future.

The markedly high numbers of metabolic diseases in Saudi Arabia in general and in our center in particular, with mostly homogenous genotypes, paves the way for future collaboration with international parties, research centers and drug industry, to help providing treatment for our patients. This environment is ideal for wide spectrum of clinical trials of various phases, to speed up the process of new medications discovery.

The limitations of the presented cohort study are clear. These include the fact that the study is confined to a single center in one particular region and contains a small sample size; therefore, the internal and external validity of the study is threatened. Such a retrospective review increases the risk of selection and information biases. Therefore, the numbers mentioned in this study should be taken with caution until further larger studies confirm or refute such findings. The retrospective nature risks missing cases due to poor documentation. In addition, some patients with metabolic disorders may not be seen at the medical center due to early death prior metabolic intervention. In addition, cases with a relatively mild disease may never have presented to the specialized metabolic center, which also contributes to the bias inherent in this study. The variability in ages at diagnosis is attributed to the delay in referring cases to the metabolic facility from other departments, and these numbers should not reflect the expected age of presentation for the listed diseases.

The incredibly high rate of IEMs in Saudi Arabia compels the health care administration in the country to develop a long-term strategic plan for the prevention of such disorders. First, a national registry should be implemented, and through that registry, a determination of the most common IEM and most common mutations in the population can be made. Second, genetic screening of high school students by DNA molecular testing should be performed to identify carriers for the most common disorders in the Saudi population. Premarital molecular screening can help couples, who carry the same disease causing variants, to take informed decision regarding their marriage and the consequences of their decision. Such a strategy has proven to be effective in another population \[[@CR16]\]. Finally, intensive educational campaigns aimed at the community through schools, TV, and web-based social media should be initiated.

Conclusion {#Sec5}
==========

In this study, we report the incidence, type, and distribution of IEMs presenting to King Abdulaziz Medical City (KAMC) in the middle region of Saudi Arabia over 13 years. We also identified 43 novel mutations in 37 genes. Our study emphasizes the high incidence of IEMs in the Saudi population and urges the health care administration in the country to develop a long-term strategic plan for the prevention of such disorders, including an IEMs national registry and a high school carrier screening program.
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